Please use this identifier to cite or link to this item: http://localhost:8080/xmlui/handle/123456789/3970
Full metadata record
DC FieldValueLanguage
dc.contributor.authorDevipriya, S-
dc.contributor.authorVijaya, M S-
dc.date.accessioned2023-11-03T06:33:43Z-
dc.date.available2023-11-03T06:33:43Z-
dc.date.issued2022-
dc.identifier.urihttps://ieeexplore.ieee.org/document/9985468-
dc.description.abstractAmyotrophic Lateral sclerosis is one of the inflammatory demyelinating diseases that affects the central nervous system. Demyelination occurs due to the attack of the immune system in the myelin layer of nerves. Because of the complexity of disorder in the nervous system, the pharmacological processes are unknown, which results in incorrect biomarker identification, uncertain targets, and unknown models. Gene signatures are employed as the primary method for treating complicated disorders. Signature based drug discovery strategy plays a vital role in predicting drug efficacy scores to reveal unknown pharmacological processes based on chemical perturbations and gene perturbations. Machine learning models with high computational and processing technologies are currently being adopted to predict drug efficacy scores by interconnecting OMICS data. This paper explores and reviews different computational models available for signature-based drug discovery and machine learning models for predicting drug efficacy scores. The results of the existing research are studied and reported.en_US
dc.language.isoen_USen_US
dc.publisherIEEEen_US
dc.titleDRUG EFFICACY SCORE PREDICTION USING SIGNATURE BASED APPROACHES FOR AMYOTROPHIC LATERAL SCLEROSIS DISORDER: A REVIEWen_US
dc.typeOtheren_US
Appears in Collections:4.Conference Paper (11)



Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.